Pliant Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Pliant Therapeutics, Inc. carries a market capitalization of 56.86M, placing it among publicly traded companies globally. Its enterprise value stands at -58.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 56.86M |
| Enterprise Value | -58.77M |
Share Statistics
Pliant Therapeutics, Inc. currently has 61.92M shares outstanding.
| Shares Outstanding | 61.92M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.48 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | -0.99 |
| P/OCF Ratio | -0.99 |
Financial Position
Pliant Therapeutics, Inc. maintains a current ratio of 9.90, meaning it holds 9.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.56, indicating elevated leverage, while an interest coverage ratio of -101.12 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.90 |
| Quick Ratio | 9.64 |
| Debt / Equity | 19.56 |
| Debt / EBITDA | -0.30 |
| Interest Coverage | -101.12 |
Financial Efficiency
| Return on Equity (ROE) | -50.29 |
| Return on Assets (ROA) | -37.69 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Pliant Therapeutics, Inc.'s stock has declined approximately -44.0061% over the past 52 weeks. The 50-day moving average sits at 1.08, while the 200-day moving average is 1.18.
| Beta (5Y) | N/A |
| 52-Week Price Change | -44.0061% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 1.18 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -96.17M, while operating income came in at -97.48M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -97.48M |
| Pretax Income | -92.29M |
| Net Income | -92.29M |
| EBITDA | -96.17M |
| EBIT | -97.48M |
| Earnings Per Share (EPS) | -1.50 |
Balance Sheet
Pliant Therapeutics, Inc. holds 158.10M in cash and equivalents against 28.74M in total debt, resulting in a net debt position of -24.88M. Total book value stands at 146.93M, with working capital of 146.66M providing operational flexibility.
| Cash & Cash Equivalents | 158.10M |
| Total Debt | 28.74M |
| Net Debt | -24.88M |
| Equity (Book Value) | 146.93M |
| Book Value Per Share | 2.37 |
| Working Capital | 146.66M |
Cash Flow
Pliant Therapeutics, Inc. produced -70.89M in operating cash flow over the past twelve months.
| Operating Cash Flow | -70.89M |
| Capital Expenditures | N/A |
| Free Cash Flow | -70.89M |
| FCF Per Share | -1.15 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 45.50 |
| FCF Yield | -100.88 |
Scores
Pliant Therapeutics, Inc. posts an Altman Z-Score of -6.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.43 |